StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.88+0.08 (+0.30%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Viking Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Viking Therapeutics's enterprise value was $2.82B on Nov 11, 2026, against $3.42B a year earlier. Over the last 5 years it ranged from -$15.87M to $7.85B, with a median of $2.23B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$2.82B-13.1%
2025Dec 31, 2025$3.24B-8.8%
2024Dec 31, 2024$3.55B+139.3%
2023Dec 29, 2023$1.49B+162.5%
2022Dec 30, 2022$565.85M+293.6%
2021Dec 31, 2021$143.75M-7.4%
2020Dec 31, 2020$155.24M-46.7%
2019Dec 31, 2019$291.42M+20.8%
2018Dec 31, 2018$241.17M+113.2%
2017Dec 29, 2017$113.14M+448.6%
2016Dec 30, 2016$20.62M-34.0%
2015Dec 31, 2015$31.22M–

More Viking Therapeutics figures

See a number that looks wrong?